Efficacy and safety of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
OBJECTIVE
To detail recent developments pertaining to the efficacy and safety of radioimmunotherapy with yttrium 90 (90Y) ibritumomab tiuxetan for patients with B-cell non-Hodgkin's lymphoma (NHL).


METHODS
Published clinical trials of 90Y ibritumomab tiuxetan and secondary literature on radioimmunotherapy and NHL.


CONCLUSIONS
Yttrium 90 ibritumomab tiuxetan is safe and effective in the indicated population. It has a good safety profile and is generally well tolerated. It is not associated with the adverse events from conventional chemotherapy and external beam radiation therapy.


CONCLUSIONS
Nursing professionals who are aware of the efficacy and safety data associated with 90Y ibritumomab tiuxetan can optimize efficacy and educate patients and their caregivers about the regimen.
Riley
Mary Beth
MB
Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA.
Gordon
Leo I
LI
D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D018951:Antigens, CD20; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D018849:Controlled Clinical Trials as Topic; D004307:Dose-Response Relationship, Radiation; D006801:Humans; D016393:Lymphoma, B-Cell / Q000451:nursing* / Q000532:radiotherapy*; D015404:Nursing Methodology Research; D009859:Oncology Nursing / Q000379:methods; D010353:Patient Education as Topic; D016499:Radioimmunotherapy / Q000379:methods / Q000451:nursing; D011879:Radiotherapy Dosage; D015021:Yttrium Radioisotopes / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D015021:Yttrium Radioisotopes; C422802:ibritumomab tiuxetan